

Australia's Nutromics raises \$14 M for ground-breaking wearable diagnostic platform

12 September 2022 | News

Aiming to cause a paradigm shift in diagnostic healthcare

Australia-based medtech startup Nutromics has raised an additional \$14 million for its wearable diagnostic platform. This transformative funding is key to Nutromics' continued expansion across Australia and the United States. Strategic investors included Dexcom Ventures, VU Venture Partners, and Artesian Investments.

This funding demonstrates a resounding level of investor confidence in the potential of Nutromics' technology, which will tackle some of healthcare's most challenging conditions through the power of continuous diagnostic monitoring. Nutromics plans to raise significantly more funding in 2023 following in-vivo clinical studies.

Nutromics is developing a wearable diagnostic platform that uses DNA technology to enable tracking for multiple targets in the human body using a single patch. This is the first technology of its kind that is both a platform and proven to work on-body. The DNA sensor technology will provide clinicians and patients with continuous and real-time diagnostic information ranging from hard-to-dose drugs, like vancomycin, to biological markers for conditions such as kidney disease.

Nutromics was founded in 2017 and including this recent acceleration round has raised over \$20 million to date for its ground-breaking wearable diagnostic platform. This latest round of funding will support an expansion of clinical studies, expansion of R&D team and investment across both Australian and United States hubs.